Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial

INTRODUCTION: Most data demonstrating the efficacy and safety of luseogliflozin (luseo) in people with type 2 diabetes mellitus (T2DM) originate from the Japanese population. This study evaluated luseo versus placebo (PCB) as add-on to metformin in a Caucasian population with inadequately controlled...

Descripción completa

Detalles Bibliográficos
Autores principales: Shestakova, Marina, Kvasnikov, Boris, Erina, Ekaterina, Isachenko, Elena, Andreev, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277051/
https://www.ncbi.nlm.nih.gov/pubmed/37328272
http://dx.doi.org/10.1136/bmjdrc-2022-003290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277051/
https://www.ncbi.nlm.nih.gov/pubmed/37328272
http://dx.doi.org/10.1136/bmjdrc-2022-003290

Ejemplares similares